Lexapro
Lexapro 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Irritable Bowel Syndrome With Constipation。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
6 项
已进入 III/IV 期
10 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- University of Michigan
- Guangdong Provincial People's Hospital
- University of Texas Southwestern Medical Center
- Poznan University of Medical Sciences
- Assistance Publique - Hôpitaux de Paris
- Northwestern University
- First Affiliated Hospital of Zhejiang University
- Duke University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
- Allergan, Inc.
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、Poland、法国、加拿大、South Korea、挪威、Turkey (Türkiye)、英国、Israel
正在招募患者的 Lexapro 研究
Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)
不适用招募中中国NCT07025590Escitalopram in Asthma Patients With Frequent Exacerbation
II 期招募中美国NCT06216535TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children
IV 期招募中PolandNCT07478796Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia
III 期招募中法国NCT07120880Pupillometry in Delayed Sleep Wake Phase Disorder
不适用招募中美国NCT06949644Chinese Longitudinal and Systematic Study of Bioplar Disorder
不适用招募中中国NCT05480150Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
不适用招募中美国加拿大NCT03511118Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
IV 期招募中美国NCT04623099Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder
不适用招募中中国NCT07480525Aβ Dynamics in LLMD
IV 期招募中美国NCT05004987Psychopharmacotherapy for Depressive Patients
不适用招募中South KoreaNCT06054321Bariatric Surgery and Pharmacokinetics of Escitalopram
不适用招募中挪威NCT03460379Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression
II 期招募中美国NCT06591091Neurobiological and Genomic Predictors of Relapse in Depression
不适用招募中Turkey (Türkiye)NCT073283737T Amygdala and Citalopram Study
不适用招募中英国NCT06412315Prediction of the Therapeutic Response in Depression Based on Neuro-computational Modeling Assessment of Motivation
不适用招募中法国NCT05866575Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD
II 期招募中中国NCT06828887A Study Utilizing Escitalopram in Glioma Patients
II 期招募中美国NCT03728673Treatment Interrupts Depression Early
II 期招募中加拿大NCT05002309Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer
不适用招募中加拿大NCT05830279Improvement of Depression With Use of ATP
不适用招募中中国NCT06266715Pattern Separation in Major Depressive Disorder
I 期招募中美国NCT07139834Trazodone on NREM Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients
IV 期招募中中国NCT06740188Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
III 期招募中IsraelNCT05603104
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。